Biotech Values

[Titan V]

CLSD shares surge 53% premarket on news of positive trial of eye disease treatment
https://www.marketwatch.com/story/clearside-biomedical-shares-surge-53-premarket-on-news-of-positive-trial-of-eye-disease-treatment-2018-03-05

Clearside Biomedical Inc. shares surged 53% in premarket trade Monday, after the company announced positive results in a late-stage trial of a treatment for macular edema associated with non-infectious uveitis, a swelling that affects the back of the eye. The company said the trial of its suprachoroidal CLS-TA involving 160 patients met its primary and secondary endpoints. "We currently expect to submit a new drug application for suprachoroidal CLS-TA in patients with macular edema associated with uveitis to the FDA in the fourth quarter of 2018, and we are also evaluating a number of options for submissions to regulatory agencies in additional territories outside of the United States," Chief Executive Daniel White said in a statement. Shares are down about 8% in the last 12 months through Friday, while the S&P 500 SPX, -0.24% has gained 13%.